Untitled

Antidepressant Drugs


Overview

  • Symptoms of Depression:
      - Feelings of sadness and hopelessness
      - Inability to experience pleasure in usual activities
      - Changes in sleep patterns and appetite
      - Loss of energy
      - Suicidal thoughts

  • Symptoms of Mania:
      - Enthusiasm, anger
      - Rapid thought and speech patterns
      - Extreme self-confidence
      - Impaired judgment


Mechanism of Antidepressant Drugs

  • Cause of Depression:
      - Due to a deficiency of monoamines (e.g., norepinephrine and serotonin) at key sites in the brain.

  • Cause of Mania:
      - Proposed to be caused by an overproduction of neurotransmitters (norepinephrine and serotonin).

  • Function of Antidepressant Drugs:
      - Potentiate the actions of norepinephrine and/or serotonin (5-HT) in the brain, either directly or indirectly.


Limitations of Biogenic Amine Theory

  • Explanation Gaps:
      - The time course for therapeutic response (usually several weeks) fails to align with the immediate pharmacodynamic effects of the agents.

  • Types of Antidepressant Drugs Used in Treatment:
      - Selective Serotonin Reuptake Inhibitors (SSRIs)
      - Serotonin/Norepinephrine Reuptake Inhibitors (SNRIs)
      - Atypical Antidepressants
      - Tricyclic Antidepressants (TCAs)
      - Monoamine Oxidase Inhibitors (MAOIs)


Selective Serotonin Reuptake Inhibitors (SSRIs)

  • Characteristics:
      - Inhibit serotonin reuptake with 300- to 3000-fold greater selectivity for serotonin transporter relative to norepinephrine transporter.
      - Contrasts with TCAs and SNRIs that nonselectively inhibit the reuptake of norepinephrine and serotonin.

  • Less Receptor Activity:
      - Little blocking activity at muscarinic, α-adrenergic, and histaminic H1 receptors.
      - Fewer common side effects than TCAs (e.g., orthostatic hypotension, sedation, dry mouth, blurred vision).

  • Examples of SSRIs:
      - Fluoxetine (prototypic drug)
      - Citalopram
      - Escitalopram
      - Fluvoxamine
      - Paroxetine
      - Sertraline


SSRIs - Actions
  • Mechanism of Action:
      - Block reuptake of serotonin, increasing concentrations of the neurotransmitter in the synaptic cleft.

  • Onset of Effects:
      - Significant improvement in mood typically takes at least 2 weeks; maximum benefit can require up to 12 weeks or longer.
      - Must maintain adequate dosage for a minimum of 6 weeks before considering treatment alteration, despite adverse effects manifesting shortly after administration.
      - Long-term use may lead to adaptive changes within synapses.


SSRIs - Variability
  • Interindividual Variations:
      - Blood levels of antidepressants can vary due to differences in drug-metabolizing enzymes and activities, affecting response rates and adverse effects.

SSRIs - Therapeutic Uses
  • Primary Indication:
      - Depression.

  • Other Psychiatric Disorders Responding Favorably to SSRIs:
      - Obsessive-compulsive disorder
      - Panic disorder
      - Generalized anxiety disorder
      - Bulimia nervosa (only Fluoxetine approved for bulimia)


SSRIs - Pharmacokinetics
  • Absorption:
      - All SSRIs are well absorbed after oral administration, with little effect from food (except Sertraline, where food increases absorption).

  • Plasma Half-Lives:
      - Most SSRIs have half-lives ranging from 16 to 36 hours.


SSRIs - Pharmacokinetics (Fluoxetine)
  • Unique Characteristics:
      - Fluoxetine has a notably longer half-life (50 hours) and its active metabolite S-norfluoxetine averages a half-life of 10 days.
      - Metabolism primarily occurs via cytochrome P450 (CYP450) dependent enzymes alongside glucuronide or sulfate conjugation.
      - Fluoxetine and Paroxetine are potent CYP450 inhibitors.

SSRIs - Adverse Effects
  • General Adverse Effects:
      - SSRIs exhibit fewer and less severe adverse effects than TCAs and MAOIs. However, potential side effects still include:
        - Anxiety and agitation
        - Sexual dysfunction
        - Gastrointestinal (GI) upset
        - Changes in weight
        - Sleep disturbances (insomnia, somnolence)
        - Drug–drug interactions

  • Serotonin Syndrome Risk:
      - All SSRIs potentially induce serotonin syndrome, particularly when used with MAOIs or other serotonergic drugs.
      - Symptoms may include hyperthermia, muscle rigidity, sweating, myoclonus (clonic muscle twitching), and changes in vital signs/mental status.
      - Treatment: Discussed in context (not detailed).


SSRIs - Use in Specific Populations
  • Sedative vs. Activating SSRIs:
      - Paroxetine, Citalopram, and Fluvoxamine are generally more sedating, beneficial for patients with sleep issues.
      - Fluoxetine and Sertraline are more activating, suitable for fatigued patients.

  • Caution with Children and Teenagers:
      - Antidepressants can increase suicidal ideation; special caution required.
      - Fluoxetine is approved for treating obsessive-compulsive disorder and childhood depression.


SSRIs - Overdose and Withdrawal
  • Overdose Risks:
      - SSRI overdose typically does not cause cardiac arrhythmias, except Citalopram (QT prolongation risk).
      - May lower seizure threshold.

  • Black Box Warning:
      - Increased risk of suicidal ideation, highlighting vigilance for children, adolescents, and young adults.

  • Discontinuation Syndrome:
      - Abrupt withdrawal may lead to discontinuation syndrome, particularly with short-half-life agents.
      - Fluoxetine has lower risk due to the long half-life.
      - Signs and symptoms may include headache, malaise, flu-like symptoms, agitation, irritability, nervousness, and sleep pattern changes.


Serotonin/Norepinephrine Reuptake Inhibitors (SNRIs)

  • Key Agents:
      - Venlafaxine, Desvenlafaxine, Duloxetine.

  • Mechanism of Action:
      - Inhibit the reuptake of both serotonin and norepinephrine.
      - Effective in patients unresponsive to SSRIs, particularly when chronic pain symptoms accompany depression.


SNRIs - Advantages and Discontinuation Syndrome
  • Receptor Activity:
      - Unlike TCAs, SNRIs have little or no activity at α-adrenergic, muscarinic, or histamine receptors, resulting in fewer receptor-mediated side effects.

  • Discontinuation Risks:
      - Abrupt cessation can precipitate discontinuation syndrome.

  • Minimal CYP450 Inhibition:
      - Venlafaxine and Duloxetine exhibit minimal inhibition of CYP450 isoenzymes.


SNRIs - Venlafaxine and Desvenlafaxine
  • Mechanism:
      - Venlafaxine inhibits serotonin reuptake and norepinephrine reuptake at medium to higher doses.
      - Desvenlafaxine is the active metabolite of Venlafaxine.

  • Common Adverse Effects:
      - GI upset, sexual dysfunction, insomnia.
      - High doses may increase blood pressure and heart rate.

  

SNRIs - Duloxetine
  • Mechanism:
      - Inhibits serotonin and norepinephrine reuptake at all doses.

  • Metabolism:
      - Extensively metabolized in the liver to inactive metabolites; avoid in patients with liver dysfunction.

  • Common Side Effects:
      - GI issues, insomnia, somnolence, sweating, sexual dysfunction, with possible increase in blood pressure or heart rate.


Tricyclic Antidepressants (TCAs)

  • Key Agents:
      - Imipramine (prototype), Amitriptyline, Doxepin, Clomipramine, Maprotiline, Amoxapine.

  • Mechanism of Action:
      1. Inhibition of Neurotransmitter Reuptake:
         - Potent inhibitors of neuronal reuptake of norepinephrine and serotonin.

      2. Blocking of Receptors:
         - Block serotonergic, α-adrenergic, histaminic, and muscarinic receptors, causing many adverse effects.
         - Amoxapine also blocks dopamine D2 receptors.


TCAs - Therapeutic Uses
  • Indications:
      - Effective for moderate to severe depression.
      - Useful in panic disorder.
      - Imipramine for bed-wetting in children over 6 years.
      - Amitriptyline for migraine prevention and chronic pain syndromes.
      - Low doses (e.g., doxepin) can induce sleep.

TCAs - Pharmacokinetics
  • Absorption and Distribution:
      - Well absorbed orally; lipophilic nature allows wide distribution, including CNS penetration.

  • Metabolism:
      - Metabolized by hepatic microsomal system and conjugated with glucuronic acid.
      - Excreted as inactive metabolites via the kidney.


TCAs - Adverse Effects
  • Muscarinic Effects:
      - Leading to blurred vision, xerostomia, urinary retention, sinus tachycardia, constipation, and aggravation of glaucoma.

  • Cardiac Risks:
      - Affect cardiac conduction like Quinidine, potentially causing life-threatening arrhythmias in overdose cases; narrow therapeutic index.

  • α-adrenergic Blocking Effects:
      - Leading to orthostatic hypotension and reflex tachycardia.

  • Sedation and Weight Gain:
      - Sedation linked to blocking histamine H1 receptors; weight gain is common.

  • Sexual Dysfunction:
      - Lower incidence than SSRIs.

  • Caution in Specific Conditions:
      - Caution in bipolar disorder, preexisting arrhythmias, epilepsy, and benign prostatic hyperplasia.


Monoamine Oxidase Inhibitors (MAOIs)

  • Enzyme Function:
      - MAO deaminates and inactivates excess neurotransmitters (norepinephrine, dopamine, serotonin).

  • Mechanism of Action:
      - MAOIs can irreversibly or reversibly inhibit MAO, allowing neurotransmitter accumulation in presynaptic neurons.

  • Available Agents:
      - Phenelzine, Selegiline.

  • Limitations:
      - Complicated dietary restrictions; not used widely due to adverse reactions.


MAOIs - Therapeutic Uses
  • Indications:
      - Unresponsive or allergic patients to TCAs and SSRIs; considered last-line treatment due to interaction risk.

MAOIs - Pharmacokinetics
  • Absorption:
      - Well absorbed orally; hepatic metabolism dominates leading to rapid urine excretion.

  • Regeneration of Enzyme:
      - Enzyme regeneration occurs weeks after stopping; need a 2-week gap when switching from MAOIs to other antidepressants.


MAOIs - Adverse Effects
  • Interactions with Tyramine:
      - Tyramine-containing foods (e.g., aged cheeses, cured meats) can induce hypertensive crisis due to MAO inhibition in gut, leading to catecholamine release.
      - Signs of hypertensive crisis: headache, tachycardia, hypertension, arrhythmias, seizures, stroke risk.

  • Management of Tyramine Hypertension:
      - Managed with Phentolamine or Prazosin.

  • SSRIs Co-administration Risks:
      - Should not be used with MAOIs (risk of serotonin syndrome); minimum washout periods required (2 weeks, 6 weeks for fluoxetine).


Atypical Antidepressants

  • Group Characteristics:
      - Mixed agents with varied actions at different neurotransmitter sites.

  • Examples:
      - Bupropion, Mirtazapine, Nefazodone, Trazodone, Vilazodone, Vortioxetine.


Atypical Antidepressant - Bupropion
  • Mechanism:
      - Weak dopamine and norepinephrine reuptake inhibitor, alleviating depression symptoms.

  • Additional Uses:
      - Useful for nicotine cravings and withdrawal symptoms in smokers.

  • Side Effects:
      - Include sweating, tremors, nervousness; increased seizure risk (thresholder).
      - Avoid in patients with seizure risk or eating disorders.


Atypical Antidepressant - Mirtazapine
  • Mechanism:
      - Enhances serotonin and norepinephrine by antagonism at presynaptic α2 and 5-HT2 receptors.
  • Sedating Nature:
      - Markedly sedating due to potent antihistaminic properties; avoids antimuscarinic side effects of TCAs.
  • Weight Impact:
      - Increased appetite; weight gain is frequent.

Atypical Antidepressants - Nefazodone and Trazodone
  • Mechanism:
      - Weak serotonin reuptake inhibitors, blocking 5-HT2 receptors post-synaptically.
  • Sedative Qualities:
      - Both have potent histamine H1-blocking activity and can be used off-label for insomnia.
  • Hepatotoxic Risk:
      - Nefazodone carries risk for hepatotoxicity.
  • Adverse Effects:
      - Orthostasis and dizziness due to mild to moderate α1 receptor antagonism.

Atypical Antidepressant - Vilazodone
  • Mechanism:
      - Serotonin reuptake inhibitor and 5-HT1a receptor partial agonist.
  • Adverse Effects:
      - Similar to SSRIs, including risk of discontinuation syndrome if stopped abruptly.

  

Serotonin-Dopamine Antagonists (SDAs)

  • Patient Response Rates:
      - 60% to 80% response to antidepressants; 20% to 40% experience partial or poor response to monotherapy.
  • Use of SDAs in Treatment:
      - Atypical antipsychotics used as adjunct treatments for partial responders.
  • Combination Example:
      - Fluoxetine with Olanzapine approved for adjunctive use in major depressive disorder (MDD).

Homework Assignments

  1. Can Vilazodone cause drug-drug interaction?
  2. Mechanism of Action (MOA) of Vortioxetine?
  3. Considerations for treating mania and bipolar disorder.
  4. Case Study Question:
       - A 77-year-old man with chronic obstructive pulmonary disease using ipratropium sprays need analysis of likely effects (options listed).